Plant Name: Brassica oleracea var. sabauda
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; HTR2C; DRD3; | |
| OPRD1; | |
| PTPN1; DUSP3; | |
| TDP1; RECQL; BLM; MIF; HPGD; AKR1B10; AKR1B1; GFER; HSD17B10; ALOX15; ALDH1A1; USP2; APEX1; POLB; | |
| GAA; | |
| TRPA1; | |
| FLT4; EPHB4; TEK; PDGFRB; AKT1; MET; INSR; NUAK1; IGF1R; ERBB2; EGFR; FYN; PLK4; AURKA; PLK1; KDR; GSK3B; SRC; MAP3K8; BRAF; AURKB; PTK2; CSNK2A1; | |
| CA2; CA1; CA12; CA9; CA13; CA14; CA7; CA5A; CA4; CA6; | |
| KDM4E; | |
| BACE1; | |
| CASP1; CASP7; | |
| VCP; | |
| SLC22A6; | |
| HBB; SMAD3; LMNA; MCL1; HSPA1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP1A2; |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Endoplasmic reticular retrotranslocon family | VCP | Transitional endoplasmic reticulum ATPase | P55072 | CHEMBL1075145 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
| Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
| Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
| Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.467E-10 | 6.423E-08 | EGFR, FYN, IGF1R, INSR, KDR, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.450E-09 | 3.036E-07 | ALOX15, BRAF, EGFR, FLT4, HTR2C, KDR, MIF, PDGFRB, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.642E-09 | 5.091E-07 | EGFR, ERBB2, FYN, INSR, MET, PDGFRB, PTK2, SRC, TEK |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.368E-08 | 2.327E-06 | AKT1, BLM, BRAF, CASP1, CSNK2A1, EGFR, ERBB2, FLT4, FYN, HPGD, IGF1R, KDR, MCL1, MET, MIF, PLK1, PLK4, SLC22A6, SMAD3, TRPA1, USP2, VCP |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.584E-08 | 2.652E-06 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.644E-08 | 2.733E-06 | EGFR, ERBB2, INSR, KDR |
| MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 1.704E-07 | 2.209E-05 | AKT1, EGFR, ERBB2, FLT4, MET, PTPN1, VCP |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.553E-07 | 3.195E-05 | CA2, CA4, CA9, EGFR, ERBB2, HPGD, SLC22A6, TEK |
| BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 2.935E-07 | 3.590E-05 | AKT1, EGFR, HBB, INSR, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 3.667E-07 | 4.270E-05 | AKT1, AURKA, GSK3B, HSPA1A, PLK1, VCP |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 5.592E-07 | 6.376E-05 | AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX15, AURKA, AURKB, BLM, BRAF, CA1, CA13, CA2, CA7, CASP1, CASP7, CSNK2A1, DUSP3, EPHB4, ERBB2, FYN, GFER, GSK3B, HBB, HPGD, HSPA1A, LMNA, MAP3K8, MCL1, MIF, PLK1, PLK4, PTK2, PTPN1, SMAD3, SRC, VCP |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 5.977E-07 | 6.744E-05 | CA2, CA7, DRD3, FYN, HTR2C, KDR, SRC, TRPA1 |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 6.145E-07 | 6.898E-05 | AKT1, AURKA, BRAF, DUSP3, EGFR, GSK3B, PDGFRB, PLK1, PTK2, PTPN1, SMAD3, SRC |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 6.577E-07 | 7.344E-05 | AURKB, CA2, CA7, DRD3, EGFR, FYN, HTR2C, KDR, MIF, SRC, TRPA1 |
| BP | Unclassified; | GO:0006461; protein complex assembly | 7.224E-07 | 7.712E-05 | BLM, BRAF, GSK3B, HBB, HSD17B10, HSPA1A, IGF1R, INSR, MIF, PTK2, SLC22A6, SMAD3, SRC, TEK, TRPA1, VCP |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 7.442E-07 | 7.867E-05 | BACE1, EGFR, FYN, INSR, KDR, OPRD1, SLC22A6, SRC, TEK |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 9.454E-07 | 9.756E-05 | AKT1, HSPA1A, MCL1, MIF, PTPN1, SRC |
| BP | GO:0050896; response to stimulus | GO:0042542; response to hydrogen peroxide | 2.009E-06 | 1.862E-04 | AKR1B1, APEX1, HBB, PDGFRB, SRC, TRPA1 |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 2.539E-06 | 2.313E-04 | AKT1, AURKA, AURKB, BLM, CSNK2A1, MIF, NUAK1 |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 2.941E-06 | 2.657E-04 | FYN, IGF1R, INSR, PDGFRB |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 3.273E-06 | 2.909E-04 | FYN, KDR, PDGFRB, PTK2, TEK |
| MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 3.273E-06 | 2.909E-04 | EGFR, ERBB2, FYN, MET, PDGFRB |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 3.385E-06 | 2.996E-04 | PDGFRB, PTK2, SRC, TEK |
| BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 4.418E-06 | 3.788E-04 | EPHB4, GAA, INSR, PTK2 |
| BP | GO:0009987; cellular process | GO:0051495; positive regulation of cytoskeleton organization | 5.001E-06 | 4.224E-04 | ALOX15, BRAF, HSPA1A, MET, PLK4, SMAD3, TEK |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 5.043E-06 | 4.224E-04 | FLT4, FYN, KDR, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:2001240; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 5.668E-06 | 4.675E-04 | AKT1, FYN, HSPA1A, MCL1 |
| BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 5.900E-06 | 4.830E-04 | AKT1, EGFR, FYN, PLK1, SMAD3, SRC |
| BP | GO:0009987; cellular process | GO:0006974; cellular response to DNA damage stimulus | 6.079E-06 | 4.958E-04 | AKT1, APEX1, AURKA, BLM, MCL1, MIF, NUAK1, PLK1, POLB, RECQL, TDP1, VCP |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 6.588E-06 | 5.333E-04 | AKR1B1, AKT1, EGFR, HPGD, PDGFRB |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 7.027E-06 | 5.667E-04 | ALOX15, EGFR, ERBB2, PDGFRB, SMAD3 |
| BP | GO:0050896; response to stimulus | GO:0034405; response to fluid shear stress | 8.010E-06 | 6.251E-04 | AKT1, CA2, PDGFRB, SRC |
| BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 8.929E-06 | 6.894E-04 | AKT1, CASP1, CASP7, PTK2 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.185E-05 | 8.778E-04 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 1.310E-05 | 9.569E-04 | AKR1B1, AKR1B10, AKT1, ALDH1A1, CYP1A2, DRD3, EGFR, HBB, HSPA1A, VCP |
| BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 1.762E-05 | 1.241E-03 | FLT4, KDR, PDGFRB |
| BP | GO:0009987; cellular process | GO:0070507; regulation of microtubule cytoskeleton organization | 1.866E-05 | 1.294E-03 | AURKA, GSK3B, HSPA1A, MET, PLK1, PLK4 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 2.002E-05 | 1.371E-03 | DRD3, EGFR, EPHB4, ERBB2, FLT4, GPR35, HPGD, HTR2C, IGF1R, INSR, KDR, MET, OPRD1, PDGFRB, TEK |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.026E-05 | 1.383E-03 | BLM, CA1, CA12, CA13, CA2, CA4, CA5A, CA6, CA7, CA9, PTPN1, SMAD3 |
| BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 2.163E-05 | 1.458E-03 | MCL1, PTK2, SRC |
| BP | GO:0008152; metabolic process | GO:0033138; positive regulation of peptidyl-serine phosphorylation | 2.399E-05 | 1.587E-03 | AKT1, BRAF, EGFR, MIF, OPRD1 |
| BP | GO:0008152; metabolic process | GO:0046854; phosphatidylinositol phosphorylation | 2.399E-05 | 1.587E-03 | EGFR, ERBB2, FYN, MET, PDGFRB |
| MF | GO:0098772; molecular function regulator | GO:0005088; Ras guanyl-nucleotide exchange factor activity | 2.447E-05 | 1.615E-03 | EGFR, ERBB2, FYN, MET, PDGFRB, PTK2, TEK |
| CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 3.406E-05 | 2.150E-03 | AURKA, AURKB, PLK1, POLB |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.548E-05 | 2.207E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 3.649E-05 | 2.255E-03 | AKR1B1, AKT1, APEX1, EGFR, SRC |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 5.400E-05 | 3.161E-03 | AKR1B1, APEX1, BLM, BRAF, EGFR, KDR, SRC |
| BP | GO:0050896; response to stimulus | GO:0009612; response to mechanical stimulus | 5.864E-05 | 3.371E-03 | AKT1, CASP1, EGFR, FYN, SRC, TRPA1 |
| BP | GO:0032501; multicellular organismal process | GO:0044057; regulation of system process | 7.287E-05 | 4.058E-03 | AKT1, DRD3, EGFR, GAA, GPR35, HTR2C, LMNA, OPRD1, SMAD3 |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 7.346E-05 | 4.081E-03 | AKR1B1, APEX1, AURKA, CA4, EGFR, ERBB2, HSPA1A, SRC, USP2, VCP |
| CC | GO:0043226; organelle | GO:0031982; vesicle | 7.413E-05 | 4.107E-03 | AKR1B1, AKR1B10, AKT1, ALDH1A1, BACE1, CA1, CA2, CA4, CA6, DRD3, DUSP3, EGFR, EPHB4, FYN, GAA, HBB, HPGD, HSPA1A, INSR, KDR, MIF, OPRD1, PDGFRB, PTPN1, SLC22A6, SRC, VCP |
| MF | Unclassified; | GO:0032403; protein complex binding | 8.370E-05 | 4.580E-03 | APEX1, EGFR, FYN, IGF1R, INSR, KDR, PLK1, PTPN1, SMAD3, SRC, VCP |
| BP | GO:0009987; cellular process | GO:0032465; regulation of cytokinesis | 9.110E-05 | 4.947E-03 | AURKA, AURKB, DRD3, PLK1 |
| CC | GO:0044464; cell part | GO:0031234; extrinsic component of cytoplasmic side of plasma membrane | 1.139E-04 | 5.933E-03 | ALOX15, FYN, PTK2, SRC |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 1.177E-04 | 6.060E-03 | BLM, RECQL |
| CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 1.177E-04 | 6.060E-03 | AURKA, AURKB |
| BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 1.237E-04 | 6.324E-03 | AKR1B1, AKT1, EGFR, KDR, PDGFRB, SLC22A6, SRC |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 1.289E-04 | 6.544E-03 | ALOX15, GSK3B, HSPA1A, MET, SRC, VCP |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.367E-04 | 6.873E-03 | AKR1B1, AKT1, APEX1, AURKA, AURKB, BLM, CASP7, CSNK2A1, DUSP3, GSK3B, HPGD, HSPA1A, LMNA, MCL1, MIF, NUAK1, PLK1, POLB, RECQL, SMAD3, SRC, USP2, VCP |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.488E-04 | 7.416E-03 | AKT1, APEX1, AURKB, MIF, PDGFRB, POLB |
| BP | GO:0008152; metabolic process | GO:0042743; hydrogen peroxide metabolic process | 1.514E-04 | 7.461E-03 | CYP1A2, EGFR, HBB |
| BP | GO:0050896; response to stimulus | GO:1904645; response to amyloid-beta | 1.514E-04 | 7.461E-03 | FYN, GSK3B, IGF1R |
| CC | GO:0044464; cell part | GO:0043209; myelin sheath | 1.576E-04 | 7.727E-03 | CA13, CA2, ERBB2, MIF, VCP |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 1.638E-04 | 7.963E-03 | AKT1, AURKA, AURKB, CSNK2A1, DRD3, DUSP3, GPR35, GSK3B, IGF1R, MET, PLK1, PTPN1, SRC |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.673E-04 | 8.022E-03 | AKT1, CYP1A2, EGFR |
| CC | GO:0043226; organelle | GO:0051233; spindle midzone | 1.673E-04 | 8.022E-03 | AURKA, AURKB, PLK1 |
| BP | GO:0009987; cellular process | GO:0035791; platelet-derived growth factor receptor-beta signaling pathway | 1.762E-04 | 8.305E-03 | PDGFRB, PTPN1 |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.762E-04 | 8.305E-03 | ALOX15, HPGD |
| MF | GO:0003824; catalytic activity | GO:0035174; histone serine kinase activity | 1.762E-04 | 8.305E-03 | AURKA, AURKB |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.762E-04 | 8.305E-03 | CA1, CA2 |
| CC | GO:0044464; cell part | GO:0097443; sorting endosome | 1.762E-04 | 8.305E-03 | KDR, PTPN1 |
| BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 1.799E-04 | 8.462E-03 | AKR1B1, AKT1, EGFR, SRC |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 1.887E-04 | 8.759E-03 | CASP1, CASP7, SMAD3, VCP |
| BP | GO:0032501; multicellular organismal process | GO:0003018; vascular process in circulatory system | 2.017E-04 | 9.260E-03 | AKT1, EGFR, HBB, SRC, TEK |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 2.167E-04 | 9.893E-03 | ALDH1A1, EGFR, IGF1R, INSR |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.696E-22 | 8.049E-18 | CA1, CA12, CA13, CA14, CA2, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.587E-18 | 1.408E-14 | CA1, CA12, CA13, CA14, CA2, CA4, CA5A, CA6, CA7, CA9, HBB |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.634E-15 | 4.655E-12 | CA1, CA12, CA13, CA2, CA4, CA5A, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.162E-13 | 7.229E-11 | AKT1, AURKA, AURKB, BLM, BRAF, CSNK2A1, EGFR, EPHB4, ERBB2, FLT4, FYN, GSK3B, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MET, NUAK1, PDGFRB, PLK1, PLK4, PTK2, RECQL, SRC, TEK, VCP |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.682E-21 | 2.708E-19 | CA12; CA1; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 5.359E-14 | 4.314E-12 | PTPN1; SMAD3; CSNK2A1; SRC; INSR; ERBB2; FYN; MET; EGFR; IGF1R |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.214E-13 | 6.514E-12 | PDGFRB; GSK3B; SRC; FLT4; BRAF; PTK2; EGFR; IGF1R; ERBB2; KDR; AKT1; FYN; MET |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.064E-10 | 4.281E-09 | PDGFRB; SRC; INSR; FLT4; KDR; AKT1; BRAF; TEK; MET; EGFR; IGF1R |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.288E-09 | 4.146E-08 | PDGFRB; GSK3B; INSR; FLT4; KDR; AKT1; TEK; MET; PTK2; EGFR; IGF1R; MCL1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.462E-08 | 4.403E-07 | SRC; ERBB2; KDR; AKT1; BRAF; MET; PTK2; EGFR; IGF1R |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.904E-08 | 3.831E-07 | PDGFRB; GSK3B; ERBB2; AKT1; BRAF; EGFR; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.623E-08 | 3.733E-07 | GSK3B; SRC; ERBB2; AKT1; BRAF; EGFR; PTK2 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.451E-08 | 3.733E-07 | PLK4; SMAD3; INSR; PLK1; AKT1; BRAF; EGFR; IGF1R |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 6.441E-08 | 1.037E-06 | PDGFRB; INSR; FLT4; KDR; AKT1; TEK; MET; EGFR; IGF1R |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.357E-07 | 1.987E-06 | PDGFRB; AKT1; BRAF; MET; EGFR; IGF1R |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.678E-07 | 1.030E-05 | PDGFRB; GSK3B; SMAD3; ERBB2; AKT1; BRAF; MET; EGFR; PTK2; IGF1R |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 8.340E-07 | 1.033E-05 | GSK3B; ERBB2; AKT1; BRAF; EGFR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.563E-06 | 2.751E-05 | PDGFRB; AKT1; BRAF; EGFR; IGF1R |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.246E-06 | 1.433E-05 | INSR; ERBB2; AKT1; TEK; EGFR; IGF1R |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.766E-06 | 2.783E-05 | SMAD3; ERBB2; AKT1; BRAF; EGFR |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.981E-06 | 2.823E-05 | PDGFRB; ERBB2; AKT1; MET; EGFR |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.286E-05 | 1.937E-04 | PDGFRB; DUSP3; AKT1; BRAF; MAP3K8; EGFR; HSPA1A |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 2.526E-05 | 2.033E-04 | SMAD3; SRC; KDR; MET; EGFR; HSPA1A; IGF1R |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.705E-05 | 2.712E-04 | ERBB2; AKT1; BRAF; EGFR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.061E-05 | 9.490E-05 | SRC; ERBB2; BRAF; EGFR |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 5.199E-05 | 3.639E-04 | SRC; KDR; AKT1; PTK2 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 9.300E-05 | 5.545E-04 | GSK3B; CSNK2A1; AKT1; FYN; HSPA1A |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 3.449E-05 | 2.645E-04 | CASP7; VCP; CASP1; HSPA1A |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 6.723E-05 | 4.163E-04 | GSK3B; FYN; MET; PTK2; EPHB4 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 5.544E-05 | 3.719E-04 | GSK3B; SMAD3; AKT1; BRAF |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 6.282E-05 | 4.046E-04 | INSR; AKT1; HSPA1A; IGF1R |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.217E-04 | 6.759E-04 | PDGFRB; INSR; AKT1; FYN; EGFR |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.031E-04 | 5.927E-04 | PTPN1; GSK3B; INSR; AKT1; BRAF |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 3.279E-04 | 1.650E-03 | PLK1; AKT1; BRAF; IGF1R |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 4.091E-04 | 1.892E-03 | GSK3B; SRC; AKT1; BRAF; PTK2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.409E-04 | 1.663E-03 | SRC; AKT1; EGFR; HSPA1A |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 2.171E-04 | 1.127E-03 | PDGFRB; SRC; HTR2C; EGFR |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 7.544E-04 | 3.282E-03 | PDGFRB; SRC; BRAF; PTK2; EGFR |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 4.112E-04 | 1.892E-03 | GSK3B; AKT1; MAP3K8; FYN |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 4.913E-04 | 2.197E-03 | PTPN1; GSK3B; INSR; AKT1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.253E-03 | 5.172E-03 | CASP7; LMNA; AKT1; MCL1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.036E-03 | 4.389E-03 | GSK3B; AKT1; BRAF; EGFR |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.320E-03 | 5.313E-03 | GSK3B; SMAD3; AKT1; IGF1R |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.655E-03 | 6.195E-03 | GSK3B; CASP7; INSR; AKT1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.730E-03 | 6.331E-03 | PDGFRB; POLB; GSK3B; SMAD3; AKT1 |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.945E-03 | 6.662E-03 | PDGFRB; FLT4; KDR; MET; EGFR |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.827E-03 | 8.925E-03 | GSK3B; CASP1; AKT1; HSPA1A |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 3.128E-03 | 9.486E-03 | PDGFRB; ERBB2; HTR2C; EGFR |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.440E-03 | 8.017E-03 | BACE1; GSK3B; CASP7; HSD17B10 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.182E-03 | 9.486E-03 | PDGFRB; ERBB2; MET; EGFR; MCL1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.414E-03 | 5.553E-03 | AKT1; BRAF; MET |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.817E-03 | 6.500E-03 | GSK3B; SRC; AKT1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.128E-03 | 9.486E-03 | HPGD; MET; PTK2; IGF1R |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.890E-03 | 6.616E-03 | SMAD3; AKT1; BRAF |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 4.714E-03 | 1.293E-02 | GSK3B; CSNK2A1; AKT1; HSPA1A |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.541E-03 | 5.909E-03 | SRC; MET; EGFR |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 4.356E-03 | 1.230E-02 | TRPA1; SRC; HTR2C |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 3.875E-03 | 1.134E-02 | INSR; AKT1; IGF1R |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 2.285E-03 | 7.663E-03 | SRC; MET; PTK2 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.739E-03 | 1.293E-02 | PDGFRB; AKT1; EGFR |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 6.007E-03 | 1.560E-02 | CASP7; AKT1; MAP3K8 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.314E-03 | 1.588E-02 | ALOX15; HTR2C; BRAF |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 7.634E-03 | 1.807E-02 | GSK3B; AKT1; BRAF |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 7.987E-03 | 1.864E-02 | SRC; AKT1; FYN |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 7.290E-03 | 1.778E-02 | GSK3B; SRC; AKT1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 7.634E-03 | 1.807E-02 | OPRD1; AKT1; FYN |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 8.168E-03 | 1.867E-02 | PLK1; AURKA; IGF1R |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.395E-02 | 2.843E-02 | OPRD1; GPR35; HTR2C; DRD3 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.206E-02 | 2.553E-02 | GSK3B; SMAD3; CSNK2A1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.299E-02 | 2.681E-02 | SMAD3; SRC; AKT1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 8.350E-03 | 1.867E-02 | INSR; AKT1; IGF1R |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 9.300E-03 | 2.051E-02 | GSK3B; AKT1; DRD3 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 8.350E-03 | 1.867E-02 | GSK3B; SMAD3; PLK1 |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 1.138E-02 | 2.476E-02 | CSNK2A1; SRC; AKT1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.367E-04 | 7.338E-04 | AKR1B10; GAA; AKR1B1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.855E-02 | 3.472E-02 | OPRD1; INSR; AKT1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.494E-02 | 4.511E-02 | GSK3B; AKT1 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 2.185E-02 | 3.997E-02 | AKT1; FYN |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.622E-02 | 4.691E-02 | CASP7; CASP1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.515E-02 | 3.050E-02 | INSR; AKT1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.727E-02 | 3.271E-02 | AKT1; BRAF |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.008E-02 | 3.716E-02 | CYP1A2; ALDH1A1 |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 1.727E-02 | 3.271E-02 | BRAF; IGF1R |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.567E-02 | 3.115E-02 | AKT1; BRAF |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.673E-02 | 3.245E-02 | AKR1B10; AKR1B1 |
| hsa05144 | Malaria_Homo sapiens_hsa05144 | 1.175E-02 | 2.522E-02 | HBB; MET |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.221E-02 | 2.553E-02 | INSR; IGF1R |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 6.125E-03 | 1.565E-02 | FYN; HSPA1A |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.234E-03 | 1.217E-02 | CYP1A2; ALOX15 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 5.139E-03 | 1.379E-02 | AKR1B10; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 5.459E-03 | 1.441E-02 | POLB; APEX1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 6.472E-03 | 1.603E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.673E-03 | 8.606E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.664E-02 | 3.245E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | ERBB2 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; ERBB2 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2C |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MIF |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Breast cancer | C50 | INSR; KDR; KDR; KDR; CA9; ERBB2; ERBB2; ERBB2; EGFR; EGFR; EGFR; IGF1R |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
| C00-D49: Neoplasms | Bladder cancer | C67 | ERBB2; EGFR |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; PDGFRB; INSR; AKR1B1; GSK3B; HTR2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; OPRD1; AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | BRAF; BRAF; FLT4; TEK; AKT1; MET; CA1; KDR; SRC; CA9; CSNK2A1; ERBB2; ERBB2; EGFR; EPHB4; MCL1; AURKA; PLK1; GSK3B; PTK2; IGF1R |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | FLT4; MET; KDR; IGF1R |
| C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD3; HTR2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3 |
| C00-D49: Neoplasms | Solid tumors | NA | BRAF |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT4; AURKB; TEK; PDGFRB; AKT1; MET; KDR; KDR; KDR; SRC; CA9; ERBB2; EGFR; AURKA; PLK1; PLK1; PTK2; IGF1R |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR; IGF1R |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TEK; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| NA: NA | Edema | NA | CA2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT4; ERBB2; EGFR; PLK1 |
| NA: NA | Primary insomnia | NA | HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR; ERBB2; EGFR; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1; MET |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; GSK3B |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | ERBB2; PLK1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PDGFRB; MET; KDR; EGFR; EGFR; IGF1R; IGF1R |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | KDR; ERBB2; EGFR; EGFR; IGF1R |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; AURKA; PLK1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HTR2C; HTR2C |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; KDR |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1; HTR2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | BRAF |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; KDR; EGFR; PLK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | OPRD1; INSR; TRPA1; IGF1R; HTR2C |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; AURKA; PLK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2C |
| C00-D49: Neoplasms | AML | NA | KDR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; VCP; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | OPRD1; HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | BRAF; KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ERBB2 |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1; HTR2C; HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; ERBB2; EGFR; EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD3; HTR2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF; INSR |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| C00-D49: Neoplasms | Melanoma | C43 | BRAF; KDR; KDR; EGFR |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | FLT4; EGFR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; KDR; EGFR; EGFR; EGFR; AKR1B1 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | BRAF; AURKA; PTK2 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1 |
| C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
| C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; INSR; CA9; ERBB2; EGFR; PLK1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; EGFR |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; KDR; KDR; KDR; EGFR; EGFR |